Inmb stock forecast models this week incorporate high beta trends, aligning with broader Nasdaq biotech index movement, signaling possible correlation with sector sentiment. Many institutions measure their performance against an index that approximates the local market. So they usually pay more attention to companies that are included in major indices. INmune Bio (NASDAQ: INMB) , a clinical-stage inflammation and immunology company, has successfully closed its previously announced registered direct offering. The company sold 3,000,000 shares of common stock at $6.30 per share , raising approximately $19 million in gross proceeds before deducting fees and expenses. Recent peer performance in similar biotech firms has been added to the inmb stock forecast dataset, enhancing sector-relative analysis accuracy.
